CanCertain (formerly CLYZ Labs) is developing a testing service to select the best drug therapy for personalised cancer treatment. CanCertain will combine information on the sensitivity of the patients own tumor cells to a range of drugs along with biomarker and treatment guidelines to provide a personalised treatment recommendation. This is expected to increase life expectancy and reduce costs by selecting the best treatment option for an individual.